Abstract
Background: Notch is a multifaceted protein that plays a fundamental role in fetal development and tissue homeostasis by directing many cellular functions, including cell growth and differentiation, cell fate determination and regulation of stem cells maintenance. The Notch family consists of four receptors (Notch 1-4) and five ligands (Jagged1-2 and Delta-like 1-3-4) widely expressed in human tissues. Given the crucial contribution of Notch signaling in many physiological processes, it is not surprising that a variety of human malignancies is characterized by a dysregulation of one or more components of this pathway.
Methods: In this review, we are going to provide a broad overview on the role of Notch pathway in solid and hematological malignancies and a survey on possible Notch-directed therapeutic strategies. Results: We present the most recent findings indicating that Notch signaling dysregulation in human cancers may be due to genetic and epigenetic alterations or to the interactions with other oncogenic pathways. Furthermore, Notch activity may have an oncogenic or a tumor suppressor effect. Finally, we describe the latest preclinical and clinical studies concerning the different pharmacological approaches targeting Notch. Conclusion: The provided evidence confirms the importance of Notch pathway in human malignancies indicating that a strong rationale exists for the development of a Notch-tailored therapy.Keywords: Notch, Dll, Jagged, therapeutic target, clinical trial, apoptosis, proliferation.
Current Pharmaceutical Design
Title:Targeting Notch as a Therapeutic Approach for Human Malignancies
Volume: 23 Issue: 1
Author(s): Natalia Platonova, Elena Lesma, Andrea Basile, Monica Bignotto, Silvia Garavelli, Maria Teresa Palano, Adriana Moschini, Antonino Neri, Michela Colombo and Raffaella Chiaramonte
Affiliation:
Keywords: Notch, Dll, Jagged, therapeutic target, clinical trial, apoptosis, proliferation.
Abstract: Background: Notch is a multifaceted protein that plays a fundamental role in fetal development and tissue homeostasis by directing many cellular functions, including cell growth and differentiation, cell fate determination and regulation of stem cells maintenance. The Notch family consists of four receptors (Notch 1-4) and five ligands (Jagged1-2 and Delta-like 1-3-4) widely expressed in human tissues. Given the crucial contribution of Notch signaling in many physiological processes, it is not surprising that a variety of human malignancies is characterized by a dysregulation of one or more components of this pathway.
Methods: In this review, we are going to provide a broad overview on the role of Notch pathway in solid and hematological malignancies and a survey on possible Notch-directed therapeutic strategies. Results: We present the most recent findings indicating that Notch signaling dysregulation in human cancers may be due to genetic and epigenetic alterations or to the interactions with other oncogenic pathways. Furthermore, Notch activity may have an oncogenic or a tumor suppressor effect. Finally, we describe the latest preclinical and clinical studies concerning the different pharmacological approaches targeting Notch. Conclusion: The provided evidence confirms the importance of Notch pathway in human malignancies indicating that a strong rationale exists for the development of a Notch-tailored therapy.Export Options
About this article
Cite this article as:
Platonova Natalia, Lesma Elena, Basile Andrea, Bignotto Monica, Garavelli Silvia, Palano Teresa Maria, Moschini Adriana, Neri Antonino, Colombo Michela and Chiaramonte Raffaella, Targeting Notch as a Therapeutic Approach for Human Malignancies, Current Pharmaceutical Design 2017; 23 (1) . https://dx.doi.org/10.2174/1381612822666161006160524
DOI https://dx.doi.org/10.2174/1381612822666161006160524 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators
Current Organic Chemistry Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry Nanoparticles in Melanoma
Current Medicinal Chemistry Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Lymphadenopathy as a Prodrome for Systemic Lupus Erythematous
Current Rheumatology Reviews Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer
Current Drug Targets Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Medicinal Chemistry The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design